Hapvida Participações e Investimentos Past Earnings Performance
Past criteria checks 0/6
Hapvida Participações e Investimentos's earnings have been declining at an average annual rate of -59.2%, while the Healthcare industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 39.3% per year.
Key information
-59.2%
Earnings growth rate
-56.3%
EPS growth rate
Healthcare Industry Growth | 11.6% |
Revenue growth rate | 39.3% |
Return on equity | -1.5% |
Net Margin | -2.7% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Hapvida Participações e Investimentos S.A.'s (BVMF:HAPV3) Popularity With Investors Is Under Threat From Overpricing
Apr 28Is Hapvida Participações e Investimentos (BVMF:HAPV3) A Risky Investment?
Mar 28Investors Still Waiting For A Pull Back In Hapvida Participações e Investimentos S.A. (BVMF:HAPV3)
Jan 07Hapvida Participações e Investimentos (BVMF:HAPV3) Is Making Moderate Use Of Debt
Dec 11Does Hapvida Participações e Investimentos (BVMF:HAPV3) Have A Healthy Balance Sheet?
Sep 11Does Hapvida Participações e Investimentos (BVMF:HAPV3) Have A Healthy Balance Sheet?
Jun 08Here's Why Hapvida Participações e Investimentos (BVMF:HAPV3) Can Afford Some Debt
Feb 27Hapvida Participações e Investimentos (BVMF:HAPV3) Has A Somewhat Strained Balance Sheet
Nov 11At R$8.13, Is It Time To Put Hapvida Participações e Investimentos S.A. (BVMF:HAPV3) On Your Watch List?
Sep 11Here's Why Hapvida Participações e Investimentos (BVMF:HAPV3) Has A Meaningful Debt Burden
Jul 08Is Now The Time To Look At Buying Hapvida Participações e Investimentos S.A. (BVMF:HAPV3)?
Mar 27We Think Hapvida Participações e Investimentos (BVMF:HAPV3) Is Taking Some Risk With Its Debt
Dec 28Is Now The Time To Look At Buying Hapvida Participações e Investimentos S.A. (BVMF:HAPV3)?
Nov 23Does Hapvida Participações e Investimentos (BVMF:HAPV3) Have A Healthy Balance Sheet?
Sep 10Should You Think About Buying Hapvida Participações e Investimentos S.A. (BVMF:HAPV3) Now?
Aug 06Does Hapvida Participações e Investimentos (BVMF:HAPV3) Have A Healthy Balance Sheet?
May 12The Hapvida Participações e Investimentos S.A. (BVMF:HAPV3) Annual Results Are Out And Analysts Have Published New Forecasts
Mar 20Introducing Hapvida Participações e Investimentos (BVMF:HAPV3), A Stock That Climbed 55% In The Last Year
Mar 10Hapvida Participações e Investimentos (BVMF:HAPV3) Has A Pretty Healthy Balance Sheet
Feb 11Is Hapvida Participações e Investimentos S.A.'s (BVMF:HAPV3) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Jan 07Investors Who Bought Hapvida Participações e Investimentos (BVMF:HAPV3) Shares A Year Ago Are Now Up 34%
Dec 10Revenue & Expenses BreakdownBeta
How Hapvida Participações e Investimentos makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 27,383 | -740 | 6,042 | 0 |
30 Sep 23 | 26,950 | -1,029 | 6,379 | 0 |
30 Jun 23 | 26,390 | -786 | 6,576 | 0 |
31 Mar 23 | 25,633 | -938 | 6,698 | 0 |
31 Dec 22 | 23,749 | -776 | 6,078 | 0 |
30 Sep 22 | 19,845 | -261 | 5,177 | 0 |
30 Jun 22 | 16,083 | -252 | 4,049 | 0 |
31 Mar 22 | 12,402 | 166 | 3,079 | 0 |
31 Dec 21 | 9,883 | 498 | 2,554 | 0 |
30 Sep 21 | 9,558 | 389 | 2,451 | 0 |
30 Jun 21 | 9,125 | 595 | 2,307 | 0 |
31 Mar 21 | 8,799 | 769 | 2,163 | 0 |
31 Dec 20 | 8,555 | 783 | 2,071 | 0 |
30 Sep 20 | 8,067 | 901 | 1,769 | 0 |
30 Jun 20 | 7,256 | 865 | 1,590 | 0 |
31 Mar 20 | 6,456 | 809 | 1,329 | 0 |
31 Dec 19 | 5,634 | 850 | 1,118 | 0 |
30 Sep 19 | 5,060 | 875 | 982 | 0 |
30 Jun 19 | 4,908 | 852 | 898 | 0 |
31 Mar 19 | 4,411 | 714 | 852 | 0 |
31 Dec 18 | 4,576 | 787 | 951 | 0 |
30 Sep 18 | 4,408 | 1,201 | 835 | 0 |
31 Mar 18 | 4,383 | 768 | 796 | 0 |
31 Dec 17 | 3,848 | 649 | 805 | 0 |
31 Dec 16 | 3,036 | 457 | 680 | 0 |
31 Dec 15 | 2,459 | 301 | 617 | 0 |
31 Dec 14 | 1,964 | 270 | 437 | 0 |
Quality Earnings: HAPV3 is currently unprofitable.
Growing Profit Margin: HAPV3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HAPV3 is unprofitable, and losses have increased over the past 5 years at a rate of 59.2% per year.
Accelerating Growth: Unable to compare HAPV3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HAPV3 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (38.6%).
Return on Equity
High ROE: HAPV3 has a negative Return on Equity (-1.51%), as it is currently unprofitable.